UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 9, 2015
bluebird bio, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
DELAWARE |
|
001-35966 |
|
13-3680878 |
|
|
|
|
|
|
|
(State or other jurisdiction of |
|
(Commission File Number) |
|
(I.R.S. Employer |
|
|
|
|
|
150 Second Street Cambridge, MA |
|
02141 |
|
|
|
|
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code (339) 499-9300
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On June 9, 2015, bluebird bio, Inc. (“bluebird”), issued a press release announcing the outcome from the National Institutes of Health Recombinant DNA Advisory Committee review of the protocol from bluebird’s proposed HGB-208 clinical trial of its LentiGlobin product candidate in pediatric subjects with Beta-thalassemia Major. The full text of bluebird’s press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
|
Description |
|
|
99.1 |
|
Press release issued by bluebird bio, Inc. on June 9, 2015, furnished herewith. |
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: June 9, 2015 |
bluebird bio, Inc.
|
|
||
|
|
By: |
/s/ Jason F. Cole |
|
|
|
|
|
Jason F. Cole |
|
|
|
|
|
Senior Vice President, General Counsel |
|
|
|
Exhibit No. |
|
Description |
|
|
99.1 |
|
Press release issued by bluebird bio, Inc. on June 9, 2015, furnished herewith. |
|